Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $6.16M rose 134.9% year over year, behind the +236.1% change in trailing-twelve-month net income. Sequentially, it fell 54.4% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Net income amounted to 53.2% of revenue in FY2025, up 18.6 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $25.2M (-7.8%) for the fiscal year ending Dec 2026, a slowdown from the +136.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.16M-54.4% QoQ
Last fiscal yearDec 2025
$27.33M+136.7% YoY
LTMMar 2026
$31.07M+236.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+134.9%-9.2%-144.1 pp
1 year+136.7%-7.8%-144.5 pp
3-year CAGR+0.9%-9.8%-10.7 pp
5-year CAGR-3.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
27.33M USD
Year-over-year change
+136.7%
4-year CAGR
+37.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +236.1% is the highest of 8, against a peer median of -56.4%.
  • Net income amounts to 61.0% of revenue for CPH.TO, versus a peer median of 15.8%.
CPH.TO Competitors
Net Income for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$263.55M CAD-56.4%-28.6%84.8%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$50.24M CAD-418.7%-39.5%15.8%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$38.02M CAD+59.5%+61.8%1377.1%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$31.07M USD+236.1%+0.9%61.0%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$25.21M CAD-249.3%—9.2%
TSND.TOTerrAscend Corp.LTM Mar 2026$20.19M USD-71.2%—7.7%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$8.81M USD-39.0%-25.7%17.2%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$5.61M CAD-49.3%-43.6%1.1%
Peer median (excluding CPH.TO) —-56.4%-28.6%15.8%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.76M26.64M20.38M11.55M27.33M
Depreciation & Amortization701K989K1.23M4.02M7.23M
Deferred Income Tax(114K)(14.31M)(2.74M)(8.64M)(10.36M)
Stock-Based Compensation139K403K1.19M1.07M1.74M
Change in Working Capital4.68M(3.03M)(3.28M)8.95M5.32M
Accounts Receivables2.56M(144K)1.71M(8.77M)2.7M
Inventory(758K)(502K)(830K)3.6M(2.44M)
Accounts Payables(1.23M)(1.45M)532K1.28M527.07K
Other Working Capital4.11M(940K)(4.69M)12.85M4.53M
Other Non-Cash Items652K(109K)(788K)2.6M(1.01M)
Operating Cash Flow13.81M10.58M16M19.55M30.25M
Capital Expenditures0(81K)(144K)(44K)(28.49K)
Acquisitions (Net)0000132.28K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(123K)(80M)0
Investing Cash Flow0(81K)(144K)(80.04M)(72.24K)
Debt Repayment(828K)(56K)(111K)39.79M(35.61M)
Common Stock Issued0000218.76K
Common Stock Repurchased(1.72M)(1.99M)(5.56M)(176K)(5.48M)
Dividends Paid00000
Other Financing Activities75K132K426K(317K)(311.36K)
Financing Cash Flow(2.47M)(1.91M)(5.24M)39.3M(41.18M)
Effect of Forex Changes62K(292K)378K(786K)(194.92K)
Net Change in Cash11.41M8.29M10.99M(21.99M)(11.2M)
Free Cash Flow13.81M10.49M15.98M19.5M30.22M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.